TVTX NASDAQ
Travere Therapeutics, Inc.
1W: -1.0%
1M: -15.9%
3M: -10.6%
YTD: +26.4%
1Y: +77.5%
3Y: +608.8%
5Y: +105.3%
$50.88
+0.91 (+1.82%)
After Hours: $52.50 (+1.62, +3.18%)
Weekly Expected Move ±6.1%
$44
$47
$50
$53
$56
Credit Risk of going bust: higher than 56% of companies Debt: 11.6% of company value Bonds: $101.5M held by 42 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.80 (down 98%), Travere Therapeutics, Inc. would be worth roughly what it owes.
Total debt $616.9M against a stock market value of $4.71B.
Distance to default 4.58 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $307.6M (short-term plus half of long-term), stock volatility 61.8%; Altman Z'' -2.95. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.80 (down 98%), Travere Therapeutics, Inc. would be worth roughly what it owes.
Total debt $616.9M against a stock market value of $4.71B.
Distance to default 4.58 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $307.6M (short-term plus half of long-term), stock volatility 61.8%; Altman Z'' -2.95. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships5
As Filer
counterparties named
2
As Counterparty
mentioned by others
4
Rel. Types
2021-09-15
Earliest Filing
2023-09-05
Latest Filing
partner: 2
acquirer: 1
investor: 1
supplier: 1
Counterparties (Filed by TVTX)
5 relationshipsCompanies named in TVTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. | MIRM | acquirer | Acquired substantially all assets related to Chenodal and Cholbam from Travere Therapeutics, Inc. | 2023-09-05 | View |
| Cooley LLP | — | investor | Legal counsel providing opinion on the validity of the securities | 2022-03-11 | View |
| Catalent Pharma Solutions, LLC | — | supplier | Commercial Supply Agreement for processing and packaging of sparsentan tablets and primary packaging. | 2021-12-22 | View |
| Vifor (International) Ltd. | — | partner | Entered into a license and collaboration agreement for commercialization of sparsentan in Europe, Australia, and New Zea | 2021-09-15 | View |
| Ligand Pharmaceuticals, Inc. | LGNZZ | partner | Existing licensor under whose agreement a sublicense to Vifor Pharma was granted. | 2021-09-15 | View |
Mentioned As Counterparty
2 mentionsOther companies that named TVTX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals, Inc. | acquirer | Target of asset acquisition for Chenodal and Cholbam products | 2023-09-05 | View |
| MIRM Mirum Pharmaceuticals, Inc. | acquirer | Mirum Pharmaceuticals agreed to purchase substantially all assets related to Chenodal and Cholbam for up to $445 million | 2023-07-17 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-21 | Officer/Director Change; Exhibits | View | |
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-07-09 | Officer/Director Change | View | |
| 2026-06-16 | Officer/Director Change | View | |
| 2026-06-02 | Material Agreement; Exhibits | Agreement | View |
| 2026-05-21 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-11 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-05-04 | Earnings Release; Exhibits | View | |
| 2026-04-14 | Other Events | View | |
| 2026-02-19 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-13 | Other Events | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-10 | Other Events | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-16 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-15 | Other Events | View | |
| 2025-05-01 | Completion of Acquisition or Disposition of Assets; Financial Statements and Exhibits | Acquisition | View |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-30 | Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR